Legal & General Group’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Legal & General Group’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-57,054	Closed	-$381K	–	3393
2023 Q3	$381K	Buy	57,054 +77	+0.1%	+$640	﹤0.01%	2541
2023 Q2	$516K	Buy	56,977 +25,706	+82%	+$227K	﹤0.01%	2454
2023 Q1	$227K	Buy	31,271 +1,334	+4%	+$9.9K	﹤0.01%	2546
2022 Q4	$218K	Buy	29,937 +1,413	+5%	+$10.5K	﹤0.01%	2578
2022 Q3	$221K	Buy	28,524 +8,203	+40%	+$69.6K	﹤0.01%	2584
2022 Q2	$139K	Buy	20,321 +13,486	+197%	+$103K	﹤0.01%	2762
2022 Q1	$54K	Hold	6,835	–	–	﹤0.01%	2993
2021 Q4	$38K	Buy	+6,835	New	+$51.3K	﹤0.01%	3096

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Legal & General Group's PNT Position: Q4 2023 in Review

Legal & General Group sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 57,054 shares — an estimated $381K sold.

Legal & General Group first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $516K in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Legal & General Group reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Legal & General Group sold 57,054 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $381K.
Legal & General Group first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Legal & General Group's POINT Biopharma Global Inc. Common Stock position peaked at $516K in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Legal & General Group's 13F filing for Q4 2023, filed 15 Feb 2024.